Spironolactone in patients with heart failure and preserved ejection fraction;Espironolactona en pacientes con insuficiencia cardiaca y fracción de eyección preservada

Revista Clinica Espanola

Volumn 215, Issue 6, 2015, Pages 301-307

  Sanchez Sanchez C ^a   Mendoza Ruiz De Zuazu, H F ^a   Formiga, F ^b   Manzano, L ^c   Ceresuela, L M ^d   Carrera Izquierdo, M ^e   Gonzalez Franco A ^f   Epelde Gonzalo, F ^b   Cerqueiro Gonzalez J M ^g   Montero Perez Barquero M ^h  

^a Servicio de Medicina Preventiva   (Spain)

^b HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^c HOSPITAL RAMÓN Y CAJAL   (Spain)

^d Sant Joan Despí   (Spain)

^e Hospital Virgen del Mirón   (Spain)

^f HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^g HOSPITAL UNIVERSITARIO LUCUS AUGUSTI   (Spain)

^h UNIVERSITY OF CÓRDOBA   (Spain)

Author keywords

Aldosterone antagonists; Diastolic heartfailure; Prognosis; Spironolactone

Indexed keywords

SPIRONOLACTONE;

AGED; ARTICLE; CARDIOVASCULAR MORTALITY; FEMALE; HEART EJECTION FRACTION; HEART FAILURE; HOSPITAL READMISSION; HUMAN; HYPERKALEMIA; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; SURVIVAL; SYSTOLIC HEART FAILURE;

EID: 84938207113     PISSN: 00142565     EISSN: 15781860     Source Type: Journal    
DOI: 10.1016/j.rce.2014.12.012     Document Type: Article

References (24)

1. B. Pitt, F. Zannad, W.J. Remme, R. Cody, A. Castaigne, A. Perez, and et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure N Engl J Med. 341 1999 709 717
2. B. Pitt, W. Remme, F. Zannad, J. Neaton, F. Martinez, B. Roniker, and et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction N Engl J Med. 348 2003 1309 1321
3. F. Zannad, J.J. McMurray, H. Krum, D.J. van Veldhuisen, K. Swedberg, H. Shi, and et al. Eplerenone in patients with systolic heart failure and mild symptoms N Engl J Med. 364 2011 11 21
4. C.W. Yanci, M. Jessup, B. Bozkurt, J. Butler, D.E. Casey, M.H. Drazner, and et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol. 62 2013 147 239
5. J.J. Mc Murray, S. Adamopoulos, S.D. Anker, A. Auricchio, M. Böhm, K. Dickstein, and et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC Eur J Heart Fail. 14 2012 803 869
6. G. Suzuki, H. Morita, T. Mishima, V.G. Sharov, A. Todor, E.J. Tanhehco, and et al. Effects of long-term monotherapy with eplerenone, a novel aldosterone blocker, on progression of left ventricular dysfunction and remodeling in dogs with heart failure Circulation. 106 2002 2967 2972
7. H. Izawa, T. Murohara, K. Nagata, S. Isobe, H. Asano, T. Amano, and et al. Mineralocorticoid receptor antagonism amioloriates left ventricular diastolic dysfunction and myocardial fibrosis in mildly symptomatic patients with idiopathic dilated cardiomyopathy: a pilot study Circulation 112 2005 2940 2945
8. P.M. Mottram, B. Haluska, R. Leano, D. Cowly, M. Stowasser, and T.H. Marwick Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failue Circulation. 110 2004 558 565
9. J. Habibi, V.G. Demarco, L. Ma, L. Pulakat, W.E. Rainey, A.T. Whaley-Connell, and et al. Mineralocorticoid receptor blockade improves diastolic function independent of blood pressure reduction in a transgenic model of RAAS overexpression Am J Physiol Heart Circ Physiol. 300 2011 H1484 H1491
10. F. Edelmann, R. Wachter, A.G. Schmidt, E. Kraigher-Krainer, C. Colantonio, W. Kamke, et al. Aldo-DHF Investigators Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial JAMA. 309 2013 781 791
11. A.H. Gradman, and J.T. Wilson Hypertension and diastolic heart failure Curr Cardiol Rep. 11 2009 422 429
12. J.I. Pérez-Calvo, M. Montero-Pérez Barquero, M. Camafort-Babkowski, P. Conthe-Gutierrez, F. Formiga, O. Aramburu-Bodas, and et al. Influence of admisión blood pressure on mortality in patients with acute descompensated heart failure QJM 104 2011 325 333
13. J.C. Trullas, F. Formiga, M. Montero, A. Conde, J. Casado, F.J. Carrasco, and et al. Paradox of obesity in heart failure: results from the Spanish RICA Registry Med Clin (Barc) 137 2011 671 677
14. A. Conde-Martel, F. Formiga, C. Pérez-Bocanegra, A. Armengol-Arxé, A. Muela-Molinero, C. Sánchez-Sánchez, and et al. Clinical characteristics and one-year survival in Herat failure patients more than 85 years of age compared with younger Eur J Intern Med 24 2013 339 345
15. W.J. Remme, and K. Swedberg Guidelines for the diagnosis and treatment of chronic heart failure. Task Force for the diagnosis and treatment of chronic heart failure, European Society of Cardiology Eur Heart J. 22 2001 1527 1560
16. M.E. Charlson, P. Pompei, K.L. Ales, and C.R. MacKenzie A new method of classifying prognostic comorbidity in longitudinal studies: development and validation J Chronic Dis. 40 1987 378 383
17. F.I. Mahoney, and D.W. Barthel Functional evaluation: the Barthel Index. A simple index of independence useful in scoring improvement in the rehabilitation of the chronically ill Md State Med J. 14 1965 61 65
18. K. Patel, G.C. Fonarow, D.W. Kitzman, I.B. Aban, T.E. Love, R.M. Allman, and et al. Aldosterone antagonists and outcomes in real-world older patients with heart failure and preserved ejection fraction JACC Heart Fail. 1 2013 40 47
19. F. Zannad Aldosterone and heart failure Eur Heart J 16 1995 98 102
20. J.G. Cleland, M. Tendera, J. Adamus, N. Freemantle, L. Polonski, and J. Taylor The perindropil in elderly people with chronic heart failure (PEP-CHF) study Eur Heart J 27 2006 2338 2345
21. B.M. Massie, P.E. Carson, J.J. McMurray, M. Komajda, R. McKelvie, M.R. Zile, and et al. Irbesartan in patients with heart failure and preserved ejection fraction N Engl J Med 359 2008 2456 2467
22. S. Yusuf, M.A. Pfeffer, K. Swedberg, C.B. Granger, P. Held, J.J. McMurray, and et al. Effects of candesartan in patients with chronic heart failure and presereved left-ventricular ejection fraction: the CHARM-Preserved Trial Lancet 362 2003 777 781
23. M.R. Zile, W.H. Gaasch, I.S. Anand, M. Haass, W.C. Little, A.B. Miller, and et al. Mode of death in patients with heart failure and a preserved ejection fraction: results from the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-Preserve) trial Circulation 121 2010 1393 1405
24. B. Pitt, M.A. Pfeffer, S.F. Assmann, R. Boineau, I.S. Anand, B. Chaggett, and et al. Spironolactone for heart failure with preserved ejection fraction N Engl J Med. 370 2014 1383 1392